May 28, 2015
The U.S. Food and Drug Administration (FDA) announced the start of a shortage of an anti-infective medication.
LG Life Sciences is experiencing a shortage of gemifloxacin mesylate (Factive) tablets as the license to manufacture the medication is under legal dispute, according to the FDA statement. Currently, there no date of recovery is listed.
Gemifloxacin mesylate tablets are indicated for susceptible strains of the bacteria that causes community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis.
The medication carries a boxed warning as use can be associated with an increased risk of tendon rupture and tendonitis.
The shortage was first posted on May 27, 2015.
1. U.S. Food and Drug Administration. FDA drug shortages. www.fda.gov. 2015 May 27.
2. FACTIVE – gemifloxacin meylate tablets. DailyMed. U.S. National Library of Medicine. Dailymed.nlm.nih.gov. Accessed May 28, 2015.